Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood. 2014 May 22;123(21):3327-35. doi: 10.1182/blood-2013-07-512855. Epub 2014 Mar 25.

Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling.

Author information

1
Department of Hematology, and.
2
Clinical Trial Center, Erasmus University Medical Center, Rotterdam, The Netherlands;
3
Delft Bioinformatics Laboratory, Delft University of Technology, Delft, The Netherlands; Netherlands Bioinformatics Centre, Nijmegen, The Netherlands;
4
University of Michigan, Ann Arbor, MI; and.
5
Department of Medicine, Hematology Oncology Division, Cornell, NY.
6
Department of Hematology, and Clinical Trial Center, Erasmus University Medical Center, Rotterdam, The Netherlands;

Abstract

Mutations in splice factor (SF) genes occur more frequently in myelodysplastic syndromes (MDS) than in acute myeloid leukemias (AML). We sequenced complementary DNA from bone marrow of 47 refractory anemia with excess blasts (RAEB) patients, 29 AML cases with low marrow blast cell count, and 325 other AML patients and determined the presence of SF-hotspot mutations in SF3B1, U2AF35, and SRSF2. SF mutations were found in 10 RAEB, 12 AML cases with low marrow blast cell count, and 25 other AML cases. Our study provides evidence that SF-mutant RAEB and SF-mutant AML are clinically, cytologically, and molecularly highly similar. An integrated analysis of genomewide messenger RNA (mRNA) expression profiling and DNA-methylation profiling data revealed 2 unique patient clusters highly enriched for SF-mutant RAEB/AML. The combined genomewide mRNA expression profiling/DNA-methylation profiling signatures revealed 1 SF-mutant patient cluster with an erythroid signature. The other SF-mutant patient cluster was enriched for NRAS/KRAS mutations and showed an inferior survival. We conclude that SF-mutant RAEB/AML constitutes a related disorder overriding the artificial separation between AML and MDS, and that SF-mutant RAEB/AML is composed of 2 molecularly and clinically distinct subgroups. We conclude that SF-mutant disorders should be considered as myeloid malignancies that transcend the boundaries of AML and MDS.

Comment in

PMID:
24668493
DOI:
10.1182/blood-2013-07-512855
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center